Your search history is turned on.
Date: February 28, 2024 Jurisdictions: All jurisdictions
Form 51102F3 MATERIAL CHANGE REPORT Item 1. Name and Address of Company ChitogenX Inc. (the Corporation) 16667, Hymus Boulevard Kirkland, QC H9H 4R9 Item 2. Date of Material Change February 28, 2024 Item 3. News Release A news release was disseminated on February 28, 2024 via CNW Cision and filed on SEDAR+. A copy of the news release...
CHITOGENX ANNOUNCES EXECUTIVE LEADERSHIP CHANGES CHITOGENX ANNOUNCES EXECUTIVE LEADERSHIP CHANGES MONTREAL, Feb. 28, 2024 /CNW/ - ChitogenX Inc. (CSE: CHGX) (OTCQB: CHNXF) ("ChitogenX" or the "Company"), a clinical-stage regenerative medicine company, today announced that Philippe Deschamps, Chief Executive Officer, has decided to step down as CEO for personal reasons and has resigned from the Board ...
Date: January 3, 2024 Jurisdictions: All jurisdictions
CHITOGENX REPORTS THIRD QUARTER 2024 RESULTS CHITOGENX REPORTS THIRD QUARTER 2024 RESULTS Launch of new skin repair development program targeting $19B in unmet medical needs Successful demonstration of protection from joint degeneration and osteoarthritis post meniscal repair surgery in ORTHO-R large animal study Conclusion of enrollment of Phase I/II clinical trial for rotator cuff tear repair Re...
Date: January 2, 2024 Jurisdictions: All jurisdictions
FORM 52-109FV2 CERTIFICATION OF INTERIM FILINGS VENTURE ISSUER BASIC CERTIFICATE I, Luc Mainville, Chief Financial Officer of ChitogenX Inc., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the interim filings) of ChitogenX Inc. (the issuer) for the interim period ended October 31, 2023. 2. No m...
FORM 52-109FV2 CERTIFICATION OF INTERIM FILINGS VENTURE ISSUER BASIC CERTIFICATE I, Philippe Deschamps, Chief Executive Officer of ChitogenX Inc., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the interim filings) of ChitogenX Inc. (the issuer) for the interim period ended October 31, 2023. 2....
MANITEX CAPITAL INC ChitogenX Inc. (previously Ortho Regenerative Technologies Inc.) Managements Discussion and Analysis for the three and nine-month periods ended October 31, 2023 (In thousands of Canadian dollars, except for units, share and per share amounts) 1 MANAGEMENTS RESPONSIBILITY FOR FINANCIAL REPORTING This Managem...
(Previously - Ortho Regenerative Technologies Inc.) Financial Report Third Quarter - Fiscal Year 2024 October 31, 2023 ChitogenX Inc. (previously Ortho Regenerative Technologies Inc.) Managements Discussion and Analysis for the three and nine-month periods ended October 31, 2023 (In thousands...
Interim Condensed Consolidated Financial Statements (Unaudited) ChitogenX Inc. October 31, 2023 Third quarter, fiscal year 2024 NOTICE OF NO AUDITOR REVIEW OF INTERIM FINANCIAL STATEMENTS Under National Instrument 51-102, Part 4, subsection ...
Date: November 9, 2023 Jurisdictions: All jurisdictions
CHITOGENX DEMONSTRATES ORTHO-R EFFICACY AND OSTEOARTHRITIS PROTECTION IN LARGE ANIMAL MENISCAL REPAIR STUDY CHITOGENX DEMONSTRATES ORTHO-R EFFICACY AND OSTEOARTHRITIS PROTECTION IN LARGE ANIMAL MENISCAL REPAIR STUDY Results demonstrate protection from knee joint degeneration and osteoarthritis development post meniscal repair surgery Results provide further evidence that the Company's proprieta...
Date: November 7, 2023 Jurisdictions: All jurisdictions
CHITOGENX LAUNCHES BURN AND SKIN REPAIR DEVELOPMENT PROGRAM CHITOGENX LAUNCHES BURN AND SKIN REPAIR DEVELOPMENT PROGRAM Significant unmet medical needs in US $19B burn and skin defects market New patent in US and Canada supports ChitogenX' proprietary chitosan-based biopolymer as ideal combination with cellular regeneration technologies Potential for streamlined regulatory process, and faster path...